Heart Failure: Management and Prognosis

Goldman's Cecil Medicine: Twenty Fourth Edition

Volumn 1, Issue , 2012, Pages 303-318

  McMurray, John J V ^a,b   Pfeffer, Marc A ^c,d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904380036     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1604-7.00059-2     Document Type: Chapter

References (56)

1. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
2. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
3. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
4. Dargie HJ Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
5. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
6. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
7. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
8. Cohn JN, Tognoni G A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
9. McMurray JJ, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
10. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
12. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
13. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
14. The Digitalis Investigation Group The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
15. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
16. Sochalski J, Jaarsma T, Krumholz HM, et al. What works in chronic care management: the case of heart failure. Health Aff (Millwood) 2009, 28:179-189.
17. O'Connor CM, Whellan DJ, Lee KL, et al. HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301:1439-1450.
18. Roy D, Talajic M, Nattel S, et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677.
19. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436-2448.
20. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
21. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
22. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010, 363:2385-2395.
23. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009, 361:1329-1338.
24. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011, 364:1607-1616. for the STICH Investigators.
25. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009, 361:2241-2251.
26. Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
27. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011, 364:797-805.
28. Weng CL, Zhao YT, Liu Qh, et al. Meta-analysis: noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med 2010, 152:590-600.
29. Joynt KE, Orav EJ, Jha AK The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure. Ann Intern Med 2011, 154:94-102. Experience is associated with better outcomes but a higher cost.
30. McMurray JJV Systolic heart failure. N Engl J Med 2010, 362:32-42. Concise review.
31. Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 2010, 122:1975-1996. Guidelines.
32. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomized controlled trial. Lancet 2010, 376:784-793. For the palliative treatment of refractory dyspnea, oxygen therapy is no more effective than room air.
33. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011, 377:658-666. In a randomized study, management based on data from an implanted wireless pulmonary artery hemodynamic monitoring system reduced hospitalization for NYHA Class III heart failure patients by over 50%.
34. Adler ED, Coldfinger JZ, Kalman J, et al. Palliative care in the treatment of advanced heart failure. Circulation 2009, 120:2597-2606. Review of end of life planning and care in patients with advanced heart failure.
35. Al-Majed NS, McAlister FA, Bakal JA, et al. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med 2011, 154:401-412. Cardiac resynchronization therapy is effective in patients with reduced LVEF, heart failure symptoms, and prolonged QRS, regardless of NYHA class.
36. Amabile CM, Spencer AP Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004, 164:709-720. Comprehensive overview, including NSAIDs.
37. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436-2448. Data suggesting that treating iron deficiency, which is common in heart failure, may improve symptoms and functional capacity.
38. Beshai JF, Grimm RA, Nagueh SF, et al. RethinQ Study Investigators. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007, 357:2461-2471. Trial showing lack of benefit of cardiac resynchronization therapy in patients without a broad QRS.
39. Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N Engl J Med 2010, 363:2301-2309. In a randomized study, telemonitoring did not significantly improve outcomes among patients recently discharged after hospitalization for heart failure.
40. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008, 10:933-989. Detailed consensus document.
41. Goldhaber JI, Hamilton MA Role of inotropic agents in the treatment of heart failure. Circulation 2010, 121:1655-1660. Review.
42. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation 2009, 119:e391-e479. Detailed consensus recommendation.
43. Jentzer JC, DeWald TA, Hernandez AF Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010, 56:1527-1534. Review emphasizing the benefits and risks.
44. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009, 360:1705-1717. Evidence that surgical left ventricular reconstruction is not beneficial in heart failure.
45. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261. Evidence that statins have little benefit in heart failure.
46. Klersy C, De Silvestri A, Gabutti G, et al. A meta-analysis of remote monitoring of heart failure patients. J Am Coll Cardiol 2009, 54:1683-1694. Systematic review of end of potential value of using technology to remotely monitor the clinical status of patients at distance.
47. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008, 358:2678-2687. Evidence that this drug is harmful in patients with severe heart failure.
48. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374:1840-1848. Evidence showing that a larger dose of angiotensin receptor blocker is more beneficial than a lower one.
49. Krum H, Abraham WT Heart failure. Lancet 2009, 373:941-955. Concise review.
50. Lahm T, McCaslin CA, Wozniak TC, et al. Medical and surgical treatment of acute right ventricular failure. J Am Coll Cardiol 2010, 56:1435-1446. Review.
51. Mark DB, Anstrom KJ, Sun JL, et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008, 359:999-1008. Evidence that implantable cardioverters do not reduce quality of life.
52. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, β-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005, 7:710-721. A clear guide to clinical prescription.
53. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999, 100:2312-2318. Trial showing that a larger dose of ACE inhibitor is more beneficial than a lower one.
54. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009, 301:383-392. Disappointing evidence that using natriuretic peptides to guide therapy may not improve outcomes in heart failure.
55. Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure. A scientific statement from the American Heart Association. Circulation 2009, 120:1141-1163. Guide to educating patients about self-management.
56. St John Sutton M, Ghio S, Plappert T, et al. REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation 2009, 120:1858-1865. Trial to support the benefits of cardiac resynchronization therapy in patients with a wide QRS but mild symptoms.